Liquid biopsy zur Individualisierung der Therapie beim fortgeschrittenen Harnblasenkarzinom

Zusammenfassung

Die Analyse von Körperflüssigkeiten („Liquid biopsy“), rückt zunehmend in den Fokus der Biomarkerentwicklung, da sie entscheidende Vorteile gegenüber der Gewebeanalyse aufweist. In den Körperflüssigkeiten können neben Proteinen und Lipoproteinen auch zirkulierende Tumorzellen (CTCs), extrazelluläre Vesikel (EVs) sowie deren Bestandteile und zellfreie Nukleinsäuren (DNA, RNA) analysiert werden. Muskelinvasive Harnblasentumore (MIHB) stellen eine besondere klinische Herausforderung dar. Hier werden neue Biomarker benötigt, um das individuelle Metastasierungsrisiko einzuschätzen, die Metastasierung im Follow-up frühzeitig zu erkennen und die effektivste systemische Therapie für den einzelnen Patienten einzusetzen. Diese Arbeit gibt einen Überblick über den aktuellen Stand zur „Liquid Biospy“ aus dem Blut bei fortgeschrittenen MIHB unter Berücksichtigung von CTCs, zirkulierender Tumor-DNA (ctDNA), nicht kodierenden RNAs (ncRNAs) sowie EVs und deren Bedeutung für Prognosebewertung und Therapieentscheidung.

Abstract

Biomarker development is focussing more and more on the analysis of body fluids (“liquid biopsy“) due to its advantages compared to tissue analysis. In addition to proteins and lipoproteins, circulating tumour cells (CTCs), extracellular vesicles (EVs) and cell-free nucleic acids (DNA, RNA) can be investigated from body fluids. Treatment of muscle-invasive balder cancer (MIBC) is still challenging. Therefore, new biomarkers are warranted to estimate the metastatic risk, to detect metastatic spread at an early time point and to select the most effective systemic therapy in a given patient. This review gives an overview of liquid biopsy from blood in patients with advanced MIBC and considers CTCs, EVs as well as circulating DNA (ctDNA) and non-coding RNA (ncRNA) and their role for prognostic evaluation and selecting treatment.

Schlüsselwörter

Biomarker - Harnblasenkarzinome - zirkulierende Tumor-DNA - microRNA - zirkulierende Tumorzellen

Keywords

bladder cancer - biomarker - circulating tumor cells - circulating tumor DNA - microRNA

Publication History

Received: 01 September 2021

Accepted after revision: 05 November 2021

Article published online:
07 December 2021

• Referenzen

• 1 Rink M, Schwarzenbach H, Riethdorf S. et al. The current role and future directions of circulating tumor cells and circulating tumor DNA in urothelial carcinoma of the bladder. World journal of urology 2019; 37: 1785-1799
• 2 Zhang Z, Fan W, Deng Q. et al. The prognostic and diagnostic value of circulating tumor cells in bladder cancer and upper tract urothelial carcinoma: a meta-analysis of 30 published studies. Oncotarget 2017; 8
• 3 Riethdorf S, Soave A, Rink M. The current status and clinical value of circulating tumor cells and circulating cell-free tumor DNA in bladder cancer. Translational andrology and urology 2017; 6: 1090-1110
• 4 Winters B, James A, Lee J. et al. Chemotherapeutic effects on circulating tumor cells in bladder cancer. Int J Urol 2015; 22: 612-613
• 5 Beije N, Kruijff IEd, Jong Jd. et al. Circulating tumor cell-driven use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer. Journal of Clinical Oncology 2021; 39: 4523-4523
• 6 Anantharaman A, Friedlander T, Lu D. et al. Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC cancer 2016; 16: 744
• 7 Skibinski DA. Noninvasive detection of PD-L1 on circulating tumor cells in patient blood samples. Future Oncol 2018; 14: 1237-1240
• 8 Postel M, Roosen A, Laurent-Puig P. et al. Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. Expert Rev Mol Diagn 2018; 18: 7-17
• 9 Green EA, Li R, Albiges L. et al. Clinical Utility of Cell-free and Circulating Tumor DNA in Kidney and Bladder Cancer: A Critical Review of Current Literature. European urology oncology 2021;
• 10 Vandekerkhove G, Lavoie JM, Annala M. et al. Plasma ctDNA is a tumor tissue surrogate and enables clinical-genomic stratification of metastatic bladder cancer. Nat Commun 2021; 12: 184
• 11 Vandekerkhove G, Todenhofer T, Annala M. et al. Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer. Clinical Cancer Research 2017; 23: 6487-6497
• 12 Christensen E, Birkenkamp-Demtroer K, Nordentoft I. et al. Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer. European urology 2017; 71: 961-969
• 13 Birkenkamp-Demtroder K, Christensen E, Nordentoft I. et al. Monitoring Treatment Response and Metastatic Relapse in Advanced Bladder Cancer by Liquid Biopsy Analysis. European urology 2018; 73: 535-540
• 14 Soave A, Chun FKH, Hillebrand T. et al. Copy number variations of circulating, cell-free DNA in urothelial carcinoma of the bladder patients treated with radical cystectomy: a prospective study. Oncotarget 2017; 8: 56398-56407
• 15 Grivas P, Lalani AKA, Pond GR. et al. Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study. European urology oncology 2020; 3: 695-699
• 16 Christensen E, Birkenkamp-Demtroder K, Sethi H. et al. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. Journal of Clinical Oncology 2019; 37
• 17 Bellmunt J, Hussain M, Gschwend JE. et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology 2021; 22: 525-537
• 18 Powles T, Assaf ZJ, Davarpanah N. et al. ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 2021;
• 19 Patel KM, van der Vos KE, Smith CG. et al. Association Of Plasma And Urinary Mutant DNA With Clinical Outcomes In Muscle Invasive Bladder Cancer. Sci Rep 2017; 7: 5554
• 20 Raja R, Kuziora M, Brohawn PZ. et al. Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. Clinical Cancer Research 2018; 24: 6212-6222
• 21 Chalfin HJ, Glavaris SA, Gorin MA. et al. Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer. European urology oncology 2021; 4: 310-314
• 22 Henriksen TV, Reinert T, Christensen E. et al. The effect of surgical trauma on circulating free DNA levels in cancer patients-implications for studies of circulating tumor DNA. Molecular oncology 2020; 14: 1670-1679
• 23 Zeuschner P, Linxweiler J, Junker K. Non-coding RNAs as biomarkers in liquid biopsies with a special emphasis on extracellular vesicles in urological malignancies. Expert Rev Mol Diagn 2019; 1-17
• 24 Linxweiler J, Junker K. Extracellular vesicles in urological malignancies: an update. Nat Rev Urol 2020; 17: 11-27
• 25 Thery C, Witwer KW, Aikawa E. et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles 2019; 8
• 26 Piao XM, Cha EJ, Yun SJ. et al. Role of Exosomal miRNA in Bladder Cancer: A Promising Liquid Biopsy Biomarker. International journal of molecular sciences 2021; 22